Mortality before hospital discharge · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Non‐pathogenic intestinal microflora (relative abundance) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Change in neuropathy symptoms · people with DPN
1 finding from 1 review
Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with DPN
1 finding from 1 review
Change in any validated quality of life score · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications of DPN · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with DPN
Alpha‐lipoic acid showed no clear difference in adverse events leading to cessation of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Mean pain intensity (Numeric Rating Scale 0–10) · lateral elbow pain
1 finding from 1 review
DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain
1 finding from 1 review
Quality of life · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global assessment of treatment success · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of withdrawals · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion with adverse events · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion with a serious adverse event · lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Erectile function · men with sexual dysfunction
3 findings from 1 review
no estimate extracted
3 studies · 792 participants
Moderate
no estimate extracted
6 studies · 2016 participants
Moderate
no estimate extracted
1 study · 42 participants
Very low
Sexual quality of life · men with sexual dysfunction
The review found no eligible studies for this question.
3 findings from 1 review